PT  - JOURNAL ARTICLE
AU  - Nichols, Emma Hitt
ED  - Taïeb, Julien
TI  - KRAS Mutations Predictive of Recurrence in Colon Cancer
DP  - 2014 Nov 01
TA  - MD Conference Express
PG  - 15--16
VI  - 14
IP  - 22
4099  - http://mdc.sagepub.com/content/14/22/15.2.short
4100  - http://mdc.sagepub.com/content/14/22/15.2.full
AB  - Codon 12 KRAS mutations are an independent predictor of time to recurrence (TTR) and disease-free survival (DFS) in patients with Stage III colon cancer who received adjuvant treatment. This article presents data from a post hoc analysis of the Combination Chemotherapy With or Without Cetuximab in Treating Patients With Stage III Colon Cancer That Was Completely Removed by Surgery trial [PETACC8; Taieb J et al. Ann Oncol 2014 (abstr O-0024)].